Syndax Pharmaceuticals Inc (SNDX): R&D Expense
$258.78M
Year ended 2025-12-31
$261.80M
Trailing 12 months to 2026-06-30
+29.7%
3-year compound annual growth
+38.7%
5-year compound annual growth
+39.1%
10-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $258.78M | +7.1% | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | $241.65M | +48.2% | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | $163.03M | +37.6% | 2026-02-26, From 2023-01-01 |
| 2022-12-31 | $118.50M | +34.3% | 2025-03-03, From 2022-01-01 |
| 2021-12-31 | $88.25M | +75.0% | 2024-02-27, From 2021-01-01 |
| 2020-12-31 | $50.44M | +17.3% | 2023-02-28, From 2020-01-01 |
| 2019-12-31 | $42.99M | -28.5% | 2022-03-01, From 2019-01-01 |
| 2018-12-31 | $60.11M | +24.7% | 2021-03-12, From 2018-01-01 |
| 2017-12-31 | $48.20M | +52.2% | 2020-03-05, From 2017-01-01 |
| 2016-12-31 | $31.66M | +231.6% | 2019-03-07, From 2016-01-01 |
| 2015-12-31 | $9.55M | -6.2% | 2018-03-08, From 2015-01-01 |
| 2014-12-31 | $10.18M | n/a | 2017-03-14, From 2014-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Syndax Pharmaceuticals Inc (SNDX) | 2025-12-31 | $258.78M | +7.1% |
| Phathom Pharmaceuticals, Inc. (PHAT) | 2025-12-31 | $32.78M | -3.8% |
| Cryoport, Inc. (CYRX) | 2025-12-31 | $17.04M | -3.8% |
| Lifevantage Corp (LFVN) | 2026-06-30 | $1.00M | -28.6% |
| Stoke Therapeutics, Inc. (STOK) | 2025-12-31 | $137.92M | +54.7% |
| Maravai Lifesciences Holdings, Inc. (MRVI) | 2025-12-31 | $17.40M | -9.5% |
| Liquidia Corp (LQDA) | 2025-12-31 | $39.28M | -17.9% |
| Rhythm Pharmaceuticals, Inc. (RYTM) | 2025-12-31 | $167.34M | -29.7% |
| Heron Therapeutics, Inc. (HRTX) | 2025-12-31 | $12.43M | -25.5% |
Compare SNDX, PHAT, CYRX, LFVN side by side · Screen every company in Pharmaceutical Preparations ↗